• LAST PRICE
    3.2000
  • TODAY'S CHANGE (%)
    Trending Up0.0900 (2.8939%)
  • Bid / Lots
    2.9000/ 1
  • Ask / Lots
    3.4000/ 6
  • Open / Previous Close
    3.0800 / 3.1100
  • Day Range
    Low 2.9400
    High 3.2300
  • 52 Week Range
    Low 2.7600
    High 15.8097
  • Volume
    17,173
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.99
TimeVolumeVACC
09:32 ET4363.11
09:45 ET1003.1
09:57 ET1822.9432
10:24 ET4003.13
10:51 ET22643.13
11:15 ET1003.045
11:31 ET1003.13
12:27 ET8503.09
12:30 ET1003.09
12:50 ET1003.13
12:52 ET39963.11
12:57 ET1003.1236
01:06 ET5003.1303
01:10 ET7003.095
01:15 ET2003.06
01:17 ET2003.14
01:19 ET2003.14
01:21 ET8002.94
01:26 ET9333.15
01:28 ET2003.12
01:30 ET1003.13
01:39 ET1503.11
02:24 ET1003.14
03:02 ET1503.194
03:09 ET1003.19
03:34 ET3003.21
03:39 ET11003.21
03:59 ET5933.2
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVACC
Vaccitech PLC
114.3M
137.9x
---
United StatesPRAX
Praxis Precision Medicines Inc
113.0M
-0.4x
---
United StatesENOB
Enochian Biosciences Inc
105.4M
-2.3x
---
United StatesGLSI
Greenwich Lifesciences Inc
112.0M
-20.1x
---
United StatesNVCT
Nuvectis Pharma Inc
112.6M
-0.2x
---
United StatesPRTG
Portage Biotech Inc
109.6M
-5.9x
---
As of 2022-10-02

Company Information

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

Contact Information

Headquarters
The Schrdinger Building Heatley Road, The Oxford Science ParkOXFORD, United Kingdom OX4 4GE
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Robin Wright
Chief Executive Officer, Director
William Enright
Chief Financial Officer
Gemma Brown
Non-Executive Director
Alex Hammacher
Non-Executive Independent Director
Karen Dawes

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$114.3M
Revenue (TTM)
$32.1M
Shares Outstanding
37.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$0.02
Book Value
$6.78
P/E Ratio
137.9x
Price/Sales (TTM)
3.6
Price/Cash Flow (TTM)
162.3x
Operating Margin
-24.18%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.